Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free CMRA Stock Alerts

Comera Life Sciences (CMRA) Competitors

Comera Life Sciences logo
Compare

CMRA vs. ARDS, SYRS, TRVN, NAVB, and PXMD

Should you buy Comera Life Sciences stock or one of its competitors? MarketBeat compares Comera Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Comera Life Sciences include Aridis Pharmaceuticals (ARDS), Syros Pharmaceuticals (SYRS), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.

How does Comera Life Sciences compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Aridis Pharmaceuticals has a beta of 49.37, meaning that its share price is 4,837% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Comera Life Sciences Neutral

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Comera Life Sciences has higher revenue and earnings than Aridis Pharmaceuticals. Comera Life Sciences is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.02
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

Summary

Aridis Pharmaceuticals beats Comera Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Comera Life Sciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Comera Life Sciences N/A N/A N/A

Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Comera Life Sciences Neutral

Comera Life Sciences has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

Summary

Comera Life Sciences beats Syros Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Comera Life Sciences compare to Trevena?

Comera Life Sciences (NASDAQ:CMRA) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Comera Life Sciences has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Trevena$443K0.02-$40.29M-$47.04N/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Trevena N/A N/A -119.55%

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Trevena Neutral

13.6% of Trevena shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Comera Life Sciences has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Trevena has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Summary

Comera Life Sciences beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Comera Life Sciences compare to Navidea Biopharmaceuticals?

Comera Life Sciences (NASDAQ:CMRA) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Comera Life Sciences has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Navidea Biopharmaceuticals Neutral

Summary

Navidea Biopharmaceuticals beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Comera Life Sciences has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Comera Life Sciences N/A N/A N/A

PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Comera Life Sciences Neutral

4.9% of PaxMedica shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Comera Life Sciences beats PaxMedica on 7 of the 9 factors compared between the two stocks.

Get Comera Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMRA vs. The Competition

Export
MetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3K$927.43M$6.46B$12.34B
Dividend YieldN/A4.84%2.76%5.28%
P/E Ratio0.001.4621.0025.66
Price / SalesN/A119.63562.1886.31
Price / CashN/A20.0743.4956.67
Price / BookN/A7.5910.417.14
Net Income-$18M-$3.64M$3.57B$335.98M

Comera Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
ARDS
Aridis Pharmaceuticals
N/A$0.00
+750.0%		N/A+750.0%$11KN/A0.0230
SYRS
Syros Pharmaceuticals
N/A$0.00
+100.0%		N/A-98.7%$11K$386KN/A120
TRVN
Trevena
N/A$0.01
flat		N/A-99.0%$11K$443KN/A40
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMRA) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel